| 42.59 -1.55 (-3.51%) | 07-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 52.45 | 1-year : | 61.26 |
| Resists | First : | 44.9 | Second : | 52.45 |
| Pivot price | 39.55  |
|||
| Supports | First : | 36.57 | Second : | 31.43 |
| MAs | MA(5) : | 42.91 |
MA(20) : | 38.8 |
| MA(100) : | 29.09 |
MA(250) : | 21.89 |
|
| MACD | MACD : | 2.6 |
Signal : | 2.2 |
| %K %D | K(14,3) : | 88.5 |
D(3) : | 90.8 |
| RSI | RSI(14): 66.1 |
|||
| 52-week | High : | 44.9 | Low : | 13.77 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ETON ] has closed below upper band by 22.7%. Bollinger Bands are 56.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 44.58 - 44.8 | 44.8 - 44.98 |
| Low: | 41.88 - 42.12 | 42.12 - 42.3 |
| Close: | 42.22 - 42.61 | 42.61 - 42.91 |
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Fri, 24 Jul 2026
The Technical Signals Behind (ETON) That Institutions Follow - Stock Traders Daily
Thu, 23 Jul 2026
Eton Pharmaceuticals stock hits all-time high at 44.0 USD By Investing.com - Investing.com Nigeria
Wed, 22 Jul 2026
Eton Pharmaceuticals: Here Is How I Handle My Position With The Stock Skyrocketing (Downgrade) - Seeking Alpha
Tue, 21 Jul 2026
Eton Pharmaceuticals (ETON) Gains On Rare Disease Momentum, Is It Still Undervalued? - Sahm
Mon, 20 Jul 2026
Eton Pharmaceuticals Inc (ETON) Shares Fall 3.1% -- What GF Scor - GuruFocus
Mon, 20 Jul 2026
Eton Pharmaceuticals (ETON) Moves 13.8% Higher: Will This Strength Last? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 27 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 4.4 (%) |
| Held by Institutions | 65.9 (%) |
| Shares Short | 1,450 (K) |
| Shares Short P.Month | 1,260 (K) |
| EPS | -0.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.12 |
| Profit Margin | -1.8 % |
| Operating Margin | 11.3 % |
| Return on Assets (ttm) | 4.7 % |
| Return on Equity (ttm) | -5.4 % |
| Qtrly Rev. Growth | 40.4 % |
| Gross Profit (p.s.) | 1.89 |
| Sales Per Share | 3.17 |
| EBITDA (p.s.) | 0.4 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 16 (M) |
| Levered Free Cash Flow | 2 (M) |
| PE Ratio | -709.84 |
| PEG Ratio | 0 |
| Price to Book value | 38.02 |
| Price to Sales | 13.41 |
| Price to Cash Flow | 73.64 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|